Inhibition of the proto-oncogene c-Myc is emerging as an attractive paradigm for the prevention and treatment of hypertrophic cardiomyopathy and heart failure.
Does c-Myc inhibition have therapeutic potential for the prevention and treatment of hypertrophic cardiomyopathy and heart failure?
Inhibition of the proto-oncogene c-Myc represents a potential future therapeutic strategy for hypertrophic cardiomyopathy and heart failure.
Investigating the pathophysiological importance of the molecular and mechanical development of cardiomyopathy is critical to find new and broader means of protection against this disease that is increasing in prevalence and impact. The current available treatment options for cardiomyopathy mainly focus on treating symptoms and strive to make the patient more comfortable while preventing progression of disease and sudden death. The proto-oncogene c-Myc (Myc) has been shown to be increased in many different types of heart disease, including hypertrophic cardiomyopathy, before any signs of the disease are present. As the mechanisms of action and multiple pathways of dependent actions of Myc are being dissected by many research groups, inhibition of Myc is becoming an attractive paradigm for prevention and treatment of cardiomyopathy and heart failure. Elucidating the role Myc plays in the development, propagation and perpetuation of cardiomyopathy and heart failure will one day translate into potential therapeutics for cardiomyopathy.
Wolfram et al. (Thu,) conducted a review in Hypertrophic cardiomyopathy. c-Myc inhibition was evaluated. Inhibition of the proto-oncogene c-Myc is emerging as an attractive paradigm for the prevention and treatment of hypertrophic cardiomyopathy and heart failure.